Zydus Lifesciences Limited has informed the Exchange regarding a press release dated August 24, 2023, titled "Zydus receives final approval from the USFDA for Zinc Sulfate Injection USP, 10 mg/10 mL (1 mg/mL), 30 mg/10 mL (3 mg/mL), and 25 mg/5 mL (5 mg/mL) Pharmacy Bulk Package Vials".
Press Release Aug 24 2023
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for a new Zinc Sulfate Injection product. The injection is intended for patients who cannot receive oral or enteral nutrition and will be manufactured at their facility in Jarod.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Aug 17 2023
- Press Release Aug 11 2023
- Press Release Aug 03 2023
- Press Release Jul 27 2023
- Press Release Jul 07 2023
Later from Zydus Lifesciences
- Press Release (Revised) Aug 24 2023
- Press Release Aug 25 2023
- Press Release Aug 31 2023
- Press Release Sep 01 2023
- Press Release Sep 13 2023
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences